A Novel Role of BIRC3 in Stemness Reprogramming of Glioblastoma

Area of Science:

• Oncology
• Cancer Biology
• Molecular Biology

Background:

• Glioblastoma (GBM) stemness reprogramming is a major cause of treatment failure.
• Identifying and targeting GBM stemness mechanisms is crucial for improving patient survival.
• BIRC3 was previously linked to therapeutic resistance and survival adaptation in GBM.

Purpose of the Study:

• To investigate the noncanonical role of BIRC3 in GBM self-renewal and stemness reprogramming.
• To elucidate the molecular mechanisms by which BIRC3 influences GBM stemness.
• To explore BIRC3 as a potential therapeutic target for reversing GBM stemness.

Main Methods:

• Utilized human and mouse GBM cell lines, and patient-derived GBM stem cells (GSCs).
• Employed BIRC3 knockout and BMP4 siRNA silencing models.
• Performed RNA-Sequencing on GBM patient tissues to analyze gene expression in hypoxic niches.
• Conducted in vivo studies using GBM orthotopic intracranial xenografts.

Main Results:

• BIRC3 was demonstrated to drive stemness reprogramming in GBM models by inactivating the BMP4 signaling axis.
• High BIRC3 and low BMP4 expression correlated in hypoxic GBM niches, validated by RNA-Seq.
• BIRC3 knockout upregulated BMP4 and prevented stemness reprogramming; BMP4 silencing restored stemness in BIRC3 knockout models.
• In vivo BIRC3 silencing suppressed GBM tumor initiation and progression.
• BIRC3 impacts stemness in both GSCs and non-GSCs, affecting intra-tumoral heterogeneity.

Conclusions:

• BIRC3 plays a critical, noncanonical role in driving GBM stemness and self-renewal through BMP4 signaling inactivation.
• Targeting BIRC3 presents a novel strategy to reverse GBM stemness reprogramming and potentially overcome therapeutic resistance.
• This finding highlights BIRC3's impact on GBM cellular heterogeneity and offers a new avenue for glioblastoma treatment.